Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: Transcriptomic expression profiling identifies ITGBL1, an epithelial to mesenchymal transition (EMT)-associated gene, is a promising recurrence prediction biomarker in colorectal cancer

Fig. 2

ITGBL1 expression in testing and validation clinical cohorts. Box plots representing ITGBL1 levels in different Tumor Node Metastasis (TNM) stages (I, II, III, and IV) in CRC: a) The testing cohort (N = 201), and d) The validation cohort (N = 468). *P < 0.05; **P < 0.01; ***P < 0.001. The prognostic significance of ITGBL1 expression was evaluated in CRC patients from two independent clinical cohorts: b, c) testing cohort, and e, f) validation cohort. Relapse-free survival in stage I-III patients (b and e) and overall survival in stage I-IV patients (c and f) were performed using the Kaplan–Meier test and the log-rank method. Forest plot of each clinicopathological factors, ITGBL1 expression for predicting RFS in stage II CRC patients of validation cohort: g) Univariate analysis, and h) Multivariate analysis. Relationship between ITGBL1 expression and RFS in stage II CRC patients of validation cohort: i) all stage II CRC patients, and j) MSS stage II CRC patients. k) Time-dependent ROC curves comparing and combining the predicting accuracy for recurrence at 5 years in stage II CRC patients

Back to article page

Molecular Cancer

ISSN: 1476-4598